Amgen (AMGN) Q1 2026: Growth Drivers Power 24% Surge, Pipeline and AI Initiatives Set New Paradigm
Amgen’s Q1 2026 results demonstrate that its six key growth drivers—now 70% of sales—are more than offsetting legacy erosion, while the company’s pipeline and AI investments reshape its long-term trajectory. The quarter marked a pivotal transition as next-generation products and disciplined R&D spend position Amgen to weather patent cliffs and intensifying biosimilar competition. With clinical momentum in obesity, rare disease, and oncology, plus operational gains from AI, Amgen raised guidance and signaled confidence in sustained innovation-led growth.
Summary
- Growth Engines Outpace Legacy Decline: Six core products now drive 70% of sales, growing 24% year-over-year.
- Pipeline and AI Integration Advance: Strategic focus on obesity, rare disease, and oncology, with AI accelerating R&D and operations.
- Guidance Raised on Execution Strength: Leadership signals confidence in new launches and sustained margin discipline.
Performance Analysis
Amgen’s first quarter performance was defined by the outsized impact of its six key growth drivers, which together generated $5.6 billion in sales and accounted for nearly 70% of total product sales. These products—spanning innovative medicines like Repatha, Avenity, and TestPy, as well as the rare disease, oncology, and biosimilars portfolios—delivered a robust 24% year-over-year sales increase. This growth decisively outpaced the continued erosion from legacy brands facing biosimilar competition, particularly in the case of Crowley and Exchiva, which saw a 32% drop as expected.
Product-level momentum was broad-based: Repatha surged 34% on guideline updates and expanded primary care penetration, Avenity grew 27% with strengthened U.S. leadership, and TestPy advanced 20% on new asthma indications. Rare disease and oncology portfolios both posted 25% gains, while biosimilars rose 14%—reflecting Amgen’s ability to balance innovation and access. Operating margin held at 45% despite a 16% increase in R&D spend, as the company doubled down on late-stage pipeline investments. Free cash flow remained strong, supporting continued capital allocation flexibility.
- Growth Driver Concentration: Six products now account for nearly three-quarters of sales, underscoring the shift away from legacy dependence.
- Balanced Portfolio Growth: Rare disease, oncology, and biosimilars all contributed double-digit increases, smoothing revenue volatility.
- Margin Resilience Amid R&D Ramp: High-margin products and cost discipline offset increased pipeline investment and royalty burden.
The quarter’s results reinforce Amgen’s strategic pivot from legacy franchises to a diversified, innovation-led model, with operational execution and pipeline depth providing a buffer against industry headwinds.
Executive Commentary
"As you can see from our progress thus far, we're on track to achieve these objectives. With steady execution through the rest of the year, we expect, once again, to demonstrate that we can grow through a period of patent expiration and deliver attractive performance for our shareholders with a strong portfolio of innovative medicines and biosimilars that meet the needs of patients with serious diseases."
Bob Bradway, Chairman and Chief Executive Officer
"We continue to expect capital expenditures of approximately $2.6 billion in 2026, reflecting significant investment in our business to scale manufacturing capacity for volume growth, including for maritime launch. We see technology and artificial intelligence as increasingly important tools to help Amgen operate with greater speed, productivity, and scale across the enterprise."
Peter Griffiths, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Growth Driver Ascendancy
Amgen’s six key growth drivers—Repatha, Avenity, TestPy, rare disease, innovative oncology, and biosimilars—are now the company’s revenue engine, delivering 24% growth and comprising nearly 70% of sales. This concentration reflects a deliberate shift away from legacy brands and positions Amgen to withstand patent expirations and biosimilar entry. The company’s commercial strategy has expanded access and broadened prescriber bases, particularly in primary care and community oncology.
2. Pipeline Depth and Differentiation
Late-stage pipeline momentum is anchored by Meritide, Amgen’s antibody-peptide conjugate for obesity and diabetes, which is progressing through multiple Phase III trials with less frequent dosing regimens and improved tolerability. The company is also advancing programs in rare autoimmune disease and oncology, including first-in-class assets like Olpaceran (siRNA for Lp(a)) and Zaluridamig (bispecific T-cell engager for prostate cancer). This breadth provides multiple shots on goal and reduces reliance on any single asset.
3. AI and Digital Transformation
Amgen is embedding artificial intelligence across R&D and manufacturing, with tangible benefits already evident in accelerated antibody discovery, improved clinical trial enrollment, and reduced production line clearance times. The company’s proprietary AI models and multi-omics data resources are expected to further compress development timelines and enhance operational efficiency, supporting both innovation and scale.
4. Capital Allocation and Financial Discipline
Despite ramped-up R&D and manufacturing investment, Amgen maintained a 45% operating margin and robust free cash flow, enabling continued share repurchases and a 6% dividend increase. Guidance for capital expenditures remains elevated to support pipeline launches, while management reiterated a disciplined approach to business development—targeting innovation that aligns with Amgen’s strengths.
5. Market Expansion and Access Initiatives
Amgen has expanded patient access through programs like Amgen Now (direct cash-pay for Repatha) and by broadening payer coverage and provider education, especially in primary prevention and rare disease segments. These initiatives aim to close treatment gaps and capture underserved patient populations as new guidelines and indications expand addressable markets.
Key Considerations
This quarter marks a strategic inflection as Amgen’s growth drivers reach critical mass, and pipeline bets in obesity, rare disease, and oncology approach pivotal readouts. Investors should weigh the durability of this growth against ongoing legacy erosion and the need for continued pipeline execution.
Key Considerations:
- Obesity Franchise Potential: Meritide’s less frequent dosing and improved tolerability could drive significant market share if Phase III data confirm differentiation.
- Cardiovascular Leadership: Repatha’s expanded primary care adoption and new guideline support create room for further penetration, especially in high-risk populations.
- AI-Driven Productivity Gains: Early wins in R&D and manufacturing efficiency hint at broader enterprise transformation and cost leverage.
- Regulatory and Competitive Landscape: Accelerated biosimilar erosion and FDA regulatory scrutiny (e.g., Tavneos) remain ongoing headwinds to legacy and niche assets.
- Tax and Legal Exposure: IRS audit and tax litigation for 2016-2018 could have material impact if adverse, though management expresses confidence in its position.
Risks
Key risks include further acceleration of biosimilar erosion, clinical or regulatory setbacks in late-stage assets (especially Meritide), and unresolved tax disputes with the IRS that could materially impact financials. The company’s guidance excludes potential M&A, and any execution missteps in integrating AI or scaling manufacturing for new launches could pressure margins or delay growth realization.
Forward Outlook
For Q2 2026, Amgen guided to:
- Operating margin in line with Q1 at 45%.
- Continued R&D investment to support late-stage pipeline progression.
For full-year 2026, management raised guidance:
- Total revenue of $37.1 billion to $38.5 billion.
- Non-GAAP EPS of $21.70 to $23.10.
Management highlighted drivers including momentum in growth products, scaling of manufacturing for pipeline launches, and AI-enabled productivity improvements.
- Pipeline milestones in obesity, rare disease, and oncology expected to read out in 2026.
- Manufacturing investments to support volume growth and new product launches.
Takeaways
Amgen’s Q1 performance underscores a successful transition to a growth-driver-led business, with robust pipeline execution and operational transformation via AI.
- Growth Outpaces Erosion: Key products now drive the majority of sales, decisively offsetting patent and biosimilar headwinds.
- Pipeline Execution Is Critical: Near-term readouts in obesity, rare disease, and oncology will determine sustainability of growth and market expansion.
- AI and Manufacturing Scale: Operational leverage from digital initiatives and capacity investment will be key to supporting next-gen launches and margin preservation.
Conclusion
Amgen’s Q1 2026 results validate its strategic pivot to innovation and operational agility, with growth drivers and pipeline momentum compensating for legacy declines. The company’s raised guidance and AI-enabled transformation set a strong foundation, but execution on upcoming clinical milestones and regulatory clarity remain central to sustaining outperformance.
Industry Read-Through
Amgen’s results signal a broader industry shift toward concentrated growth drivers and pipeline-led resilience as legacy franchises face biosimilar and generic threats. The integration of AI into both R&D and manufacturing is emerging as a competitive differentiator, compressing timelines and improving productivity. For biopharma peers, Amgen’s approach to direct patient access, expanded primary care engagement, and disciplined capital allocation provides a template for navigating patent cliffs and scaling next-generation therapies. The company’s experience with regulatory scrutiny and tax litigation also highlights the increasing complexity of operating at global scale in the sector.